H Hareyama
Overview
Explore the profile of H Hareyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
249
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ikeda K, Sakai K, Yamamoto R, Hareyama H, Tsumura N, Watari H, et al.
Int J Gynecol Cancer
. 2003 Dec;
13(6):776-84.
PMID: 14675314
It has been suggested that histologic subtype of ovarian cancer is a factor that determines the chemoresponsiveness of tumor. In this study, we wanted to clarify the prognostic significance of...
2.
Sakuragi N, Takeda N, Hareyama H, Fujimoto T, Todo Y, Okamoto K, et al.
Cancer
. 2000 Jun;
88(11):2578-83.
PMID: 10861436
Background: To the authors' knowledge there are few available data regarding the influence of lymphovascular space invasion, which has been examined separately as two components (lymphatic vessel invasion [LVI] and...
3.
Sakuragi N, Hareyama H, Todo Y, Yamada H, Yamamoto R, Fujino T, et al.
Acta Obstet Gynecol Scand
. 2000 Apr;
79(4):311-6.
PMID: 10746848
Background: The serous adenocarcinoma (SA) and clear cell adenocarcinoma (CCA) of endometrium have been shown to be associated with high relapse rate and poor survival. It is not clear whether...
4.
Sakaihara M, Sakai K, Hara Y, Kataoka S, Tabata M, Hanatani K, et al.
Gan To Kagaku Ryoho
. 2000 Feb;
27(1):127-30.
PMID: 10660745
Resistance to conventional chemotherapy including CDDP is the most important therapeutic problem in ovarian cancer. The combination chemotherapy of 5-FU (civ) and low-dose CDDP (i.v.) was applied to a patient...
5.
Sakuragi N, SATOH C, Takeda N, Hareyama H, Takeda M, Yamamoto R, et al.
Cancer
. 1999 Apr;
85(7):1547-54.
PMID: 10193945
Background: The incidence and distribution pattern of retroperitoneal lymph node metastasis in patients with cervical carcinoma should be investigated based on data from systematic pelvic lymph node (PLN) and paraaortic...
6.
Wada S, Kudo T, Kudo M, Sakuragi N, Hareyama H, Nishihira J, et al.
Hum Reprod
. 1999 Apr;
14(2):395-9.
PMID: 10099986
The role of macrophage migration inhibitory factor (MIF) in human ovarian function remains obscure. The aim of this study was to investigate how MIF was related to ovulation by quantitative...
7.
Hoshi N, Fujita M, Mikuni M, Fujino T, Okuyama K, Handa Y, et al.
J Med Genet
. 1998 Oct;
35(10):852-6.
PMID: 9783712
We report an unusual case of a 55 year old Japanese woman with a seminoma but relatively normal menses. The patient was a phenotypic female with late onset menarche (18...
8.
Tsumura N, Sakuragi N, Hareyama H, SATOH C, Oikawa M, Yamada H, et al.
Int J Cancer
. 1998 Oct;
79(5):526-30.
PMID: 9761124
The distribution of lymph node metastasis and the clinicopathologic risk factors for nodal involvement in ovarian carcinoma need to be clarified based on systematic lymph node dissection. We studied 115...
9.
Nishiya M, Sakuragi N, Hareyama H, Ebina Y, Furuya M, Oikawa M, et al.
Int J Cancer
. 1998 Oct;
79(5):521-5.
PMID: 9761123
The International Federation of Gynecology and Obstetrics (FIGO) adopted surgical staging criteria in 1988. Many studies have shown that histologic grade, nuclear grade, lymph-vascular space invasion and cell type are...
10.
Sakuragi N, Ohkouchi T, Hareyama H, Ikeda K, Watari H, Fujimoto T, et al.
Int J Cancer
. 1998 May;
79(2):153-8.
PMID: 9583730
Bcl-2 protein inhibits apoptosis, reduces the requirement for growth factors, and thereby extends the survival of cells. Recent findings of Bcl-2 in several solid tumors suggest that it might contribute...